Skip to NavigationSkip to content


NICE recommends Celgene's Revlimid in treatment-naive multiple myeloma

Celgene’s Revlimid (lenalidomide) has been recommended by NICE for use on the NHS in England and Wales in combination with dexamethasone in the treatment of previously untreated multiple myeloma, the company has announced. The expanded indication relates specifically to adult patients who are not eligible for stem cell transplant and only where thalidomide cannot be tolerated or is contraindicted.

Sorrento Therapeutics seek $1 billion from billionaire biotech investor Patrick Soon-Shiong

Image Credit: NHS Confederation

Sorrento Therapeutics is seeking $1 billion in damages from billionaire biotech investor Patrick Soon-Shiong, owner of US newspaper the LA Times.  

The legal action comes after Sorrento accused Soon-Shiong of “catching and killing” a generic version of a cancer drug, which would have acted as competition to one owned by Celgene, a company in which he was the largest shareholder.

Sorrento claim Soon-Shiong acquired Cynviloq, a generic version of Celgene’s Abraxane, with the intention of stopping its progression to market.

Celgene inks drug discovery deal worth at least £25m with AI firm Exscientia

Celgene has entered into a new three-year partnership with British artificial intelligence and drug discovery firm Exscientia to the value of at least $25 million, it has emerged, in a bid to galvanise small molecule drug discovery in oncology and autoimmunity.

Transactions stemming from the deal include this initial upfront payment in addition to “substantial” milestone payments subject to future regulatory and commercial successes.

Celgene's Abraxane combo flops in phase 3 cancer trials

Celgene’s Abraxane, in combination gemcitabine, has failed to meet its primary endpoint in a pivotal Phase 3 trial of patients with pancreatic cancer.

Celgene’s drug failed to achieve its primary endpoint of improvement in disease-free survival in patients with surgically resected pancreatic adenocarcinoma, as confirmed by independent radiological review, compared to gemcitabine alone.

Disapproval from top shareholder throws $74bn BMS/Celgene merger into doubt

The news kicked off 2009 with a bang when Bristol-Myers Squibb announced it intended to acquire Celgene for $74 billion, but what could potentially be the biggest pharmaceutical industry merger of all time has been thrown into doubt thanks to a key BMS shareholder.

Top shareholder Wellington Management, which owns around 8% of BMS shares, has announced, in a rare move, that it does not support the prospective deal on the basis that it is a risky and expensive move.

Top Ten most popular articles on this week!

While American firm AbbVie gained approval for leukaemia drug Venlytxo, the NHS defeated the US multinational thus week in court, after the firm challenged NHS England’s hep C drug procurement process, calling it ‘unfair’.

Meanwhile Sir Philip Hampton stepped down from his position as chairman of GSK while Vertex were prompted to oust current COO Ian Smith citing ‘personal behaviour’.

Celgene signs deals with two Massachusetts-based biotechs

New Jersey-based biotechnology firm Celgene has signed deals with two Massachusetts-based biotechs: immuno-oncology specialist Kyn therapeutics and cell therapy firm Obsidian.

The multibillion dollar firm will pay Kyn an upfront sum of $80 million in seeking to collaborate on the development and commercialisation of medicines in areas of high unmet need.

Top Ten most popular articles on this week!

The biggest news this week came from Israeli biotech Zion Medical after it was announced that HIV drug Gammora was able to eliminate 99% of the HIV virus within four weeks in phase 1/2a clinical trials.

Meanwhile former Celgene CEO Bob Hugin failed in his bid for electoral victory after Democrat Bob Menendez won over the people of New Jersey in the US midterms. In sticking to politics our feature ‘Vaccines in the age of populism’ discusses the rise of anti-establishment politics and the effect it has on patient adherence.

Former Celgene CEO Bob Hugin loses in US midterm elections

Former Celgene CEO Bob Hugin has failed in his bid to win over the people of New Jersey, after voters last night elected Democratic candidate Bob Menendez in the US midterm elections.

Despite receiving nearly three times as much in campaign finance, it was announced that the republican candidate lost the New Jersey Senate election, gaining 43.8% of the vote in comparison to his opponent Menendez’s 53.1% share.

Celgene's Otezla impresses at Phase 3 in scalp psoriasis

Celgene has unveiled new Phase 3 data for Otezla (apremilast), its inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP), in the treatment of moderate to severe scalp psoriasis, with users showing a “highly statistically significant” increase in Scalp Physician’s Global Assessment (ScPGA) response, achieving its primary endpoint.

Specifically, patients taking 30mg twice daily reported a ScPGA response of 0 or 1, representing clear or almost clear respectively, with at least a two-point reduction from baseline after 16 weeks, compared to placebo.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches